Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13 091, prevention strategies have the potential to reduce health-care costs.
Introduction
A number of pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). One phase III study examining finasteride has been completed and results have shown a 25% reduction in the period prevalence of PCa over 7 years. 1 Although initially the development of high-grade PCa under finasteride treatment was viewed as a detrimental effect, 1 recently published new analyses demonstrated this to be an artifact, and in fact, these analyses suggest overall a 30% reduction in the period prevalence of PCa under finasteride with no increased risk for high-grade cancer.
2-5 Dutasteride 6 is also currently being evaluated in phase III placebo-controlled trials. As additional clinical data become available regarding the benefits and risks of these pharmacologic agents, an examination of their economic impact will also be important.
Estimates of treatment costs by stage are valuable for economic evaluations because they provide insight into how costs may be impacted through prevention and/or screening strategies. Several studies have been conducted that examine the effect of PCa stage on initial treatment costs with conflicting results. [7] [8] [9] The majority of costs related to PCa occur during the period of initial treatment. Both Taplin et al. 7 and Penberthy et al. 8 reported that initial PCa stage did not affect treatment costs whereas Penson et al. 9 concluded that first-year costs do increase by stage particularly for patients treated with radical prostatectomy. The purpose of this study was to estimate first-year PCa costs and to examine the extent to which costs and utilization vary by initial stage. Although recent studies have used either the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER)-Medicare data 10, 11 or the Medicare 5% public use files, 12 to examine PCa treatment costs in Medicare beneficiaries, these studies do not report data by cancer stage.
Materials and methods

Data source
Data for this study were obtained from the SEERMedicare database. SEER is an epidemiologic surveillance system consisting of population-based tumor registries designed to track cancer incidence and survival in the United States. Data were available on incident cases representing approximately 14 and 26% of the US population for database years spanning 1991-1999 and 2000-2002, respectively. 13 Detailed clinical data are available for cancer-related diagnoses including primary site, tumor stage at diagnosis and mortality. The linkage of SEER with Medicare claims enables the longitudinal analysis of health-care utilization and costs following a cancer diagnosis.
Sample selection
All male patients aged 65 years and older who had a primary diagnosis of PCa between 1 January 1991 and 31 December 2002 and without any prior cancer diagnosis were selected from SEER. Patients were excluded if their cancer stage at diagnosis was either missing or stage 0. Additional exclusion criteria were used to ensure that utilization and cost data were complete for every patient. Patients were excluded if they were not enrolled in Medicare Parts A or B during study follow-up, were enrolled in a Medicare health maintenance organization or had Medicare eligibility based on end-stage renal disease or disability. We also excluded patients if their PCa was identified at autopsy because no follow-up medical care would have been provided. Information pertaining to cancer stage was available in SEER and defined according to the third edition of the American Joint Committee on Cancer Staging Manual.
14 Table 1 shows how the TNM (tumornode-metastases) system translates into the stage I-IV grouping.
Male patients from Medicare enrollment files representing a 5% sample of Medicare beneficiaries residing in SEER areas who were not reported to any SEER registries as having cancer were selected and matched to cases on 5-year age groups. This cohort was used to estimate the background costs unrelated to PCa. Insufficient numbers of patients precluded a 1:1 matching with PCa patients. Patients were assigned an index date so that the distribution of study start dates for the non-cancer cohort and controls followed the same calendar time period. For inclusion in the non-cancer group, patients had to be continuously enrolled in Medicare Parts A and B during study follow-up. Baseline comorbidity was assessed in PCa cases and non-cancer controls using the Deyo method in the 6 months before initial PCa diagnosis. 15 
Estimation of monthly total costs
The total average cost of medical care was calculated by summing all Medicare payments in the first year following diagnosis. This result was then divided by the average number of follow-up months patients were alive during the first treatment year to obtain average monthly total costs for patients diagnosed in each cancer stage. This calculation was also performed for the noncancer cohort using the assigned index date as the starting point of analysis. Medicare claims data from calendar years 1991 through 2003 were used to estimate mean monthly costs. This period was chosen because the main initial therapeutic options including prostatectomy, radiation and hormone therapy were all in use. The Medicare files contain claim information for inpatient and outpatient care, physician and other professional services, home health as well as hospice and skilled nursing facility care. Medicare records include data on dates of service so that the claims occurring within the first year following PCa diagnosis could be identified. Cost data were based on Medicare payments and adjusted to 2004 US constant dollars using the medical care services component of the Consumer Price Index.
Estimation of PCa-related and total first-year costs
The incremental difference in average monthly costs between PCa cases and the non-cancer cohort was assumed to be health-care costs related to PCa. Stagebased PCa-related mean monthly costs were then multiplied by the average number of months patients in each cancer stage were alive during the first year following diagnosis. Total first-year costs were estimated similarly to PCa-related costs using mean total monthly cost estimates.
Sensitivity analyses
During 2000-2002, cancer registries in Kentucky, Louisiana and New Jersey were added to the SEER database. A sensitivity analysis excluding patients from these registries was conducted to test the impact that the addition of these registries had on PCa-related costs. The main analysis was conducted on patients diagnosed with PCa spanning a 12-year period (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) . We conducted another sensitivity analysis to determine if first-year PCa-related costs for patients diagnosed during the last 5 years for which data were available (1998-2002) were similar to the primary analysis.
Statistical analyses
Confidence intervals (CIs) for cost estimates were derived by using nonparametric bootstrap methods. 16 We resampled with replacement from the study population to create 1000 random samples. All estimates of total and PCa-related costs were repeated for each of the 1000 replicates. 95% CIs were obtained from the sample distribution of costs. Survival analysis using the KaplanMeier (product-limit) method was used to compare life expectancy between study groups. All study patients had complete Medicare follow-up 6 months before PCa diagnosis until either death or the end of the first year following diagnosis. 
Abbreviations: G, histopathologic grade; G1, well-differentiated, slight anaplasia; G2, moderately differentiated, moderate anaplasia; G3-G4, poorly differentiated or undifferentiated, marked anaplasia; M, distant metastasis; M0, no distant metastasis; M1, distant metastasis; N, regional lymph nodes; N0, no regional lymph node metastasis; N1, metastasis in one lymph node, p2 cm in greatest dimension; N2, metastasis in one lymph node, 42 cm and no more than 5 cm in greatest dimension, or multiple lymph nodes, none more than 5 cm in greatest dimension; N3, metastasis in a lymph node 45 cm in greatest dimension; T, primary tumor; T1, tumor is incidental histologic finding; T1a, three or fewer microscopic foci of carcinoma; T1b, more than three microscopic foci of carcinoma; T2, tumor present clinically-limited to the gland; T2a, tumor 1.5 cm or less in greatest dimension with normal tissue on at least three sides; T2b, tumor 41.5 cm in greatest dimension or in 41 lobe; T3, tumor invades the prostatic apex, or into or beyond the prostatic capsule, bladder neck, or seminal vesicle, but is not fixed; T4, tumor is fixed or invades adjacent structures other than those listed in T3; TNM, tumornode-metastases.
First-year costs of prostate cancer CG Roehrborn et al Table 2 compares the demographic and clinical characteristics of patients with PCa to those without cancer.
Results
Patient characteristics
The non-cancer cohort was comparable to PCa patients with respect to age, survival and Charlson comorbidity score. PCa patients were slightly younger (6 months) vs the non-cancer group. The proportions of PCa patients residing in the midwest and west were higher compared to the non-cancer cohort.
Initial treatment for PCa
The use of PCa-related medical services in the first 6 months following cancer diagnosis is shown in Table 3 . Almost one-third of all PCa patients did not receive an active therapy during the 6-month initial treatment phase. These patients were slightly older (mean age: 76 years) vs patients receiving active treatment (mean age: 73.2 years). Use of prostatectomy was highest for stage III (56.4%). Receipt of external beam radiation and brachytherapy was more common among early vs higher staged patients. Very few patients received cryotherapy (0.1%) or bilateral orchidectomy (0.2%).
Monthly treatment costs Table 3 ), these patients were more likely to have multiple hospitalizations in the first treatment year (Table 3) . Hospitalizations are an important cost driver and explain the high first-year costs observed for stage IV.
Sensitivity analyses
The sensitivity analysis excluding patients from cancer registries added during 2000-2002 (Kentucky, Louisiana and New Jersey) had a minimal impact on PCa-related costs. When patients from these registries were excluded from the analysis, first-year PCa-related costs were reduced by only 5% (from $13 091 to 12 418). Results of the sensitivity analysis examining first-year PCa-related costs in patients diagnosed during 1998-2002 ($12 959) were similar to the full sample cohort diagnosed during 1991-2002 ($13 091).
Discussion
Prostate cancer-related costs in the first-year following diagnosis averaged $13 091. Costs varied by cancer stage and reflected differences in the extent to which initial therapy was utilized. Patients diagnosed at stage III received PCa-related therapy to a greater extent vs stages I and II and hence had higher first-year PCa-related costs relative to stages I and II. Stage IV patients had the highest costs. Although nearly half of stage IV patients did not receive initial treatment, these patients were more likely to have multiple hospitalizations compared to stage III, which likely was a factor in driving up costs. These results contrast with Taplin et al. 7 in that we observed increases in health-care utilization and costs among both regional and distant stages relative to local. As in our study, PCa-related costs were defined as the net costs between PCa cases and a group of age-matched controls. They sampled PCa patients during 1990-1991, whereas our study included patients diagnosed from 1990 to 2002. Unfortunately, Taplin et al. did not report data on health-care utilization so it is difficult to determine the extent to which differences between studies are related to changes in patterns of care. Our results are more consistent with Penson et al. 9 despite differences in study designs. Penson et al. used a more direct approach in estimating costs by applying Medicare reimbursement rates to medical resource use data from the CaPSURE database and only studied patients with local PCa. However, both studies observed increasing health-care costs and hospitalizations in patients with higher cancer stages.
Comparing our results to Penberthy et al. 8 gives some insight into the changes in utilization and costs occurring over time. They used the SEER-Medicare dataset to estimate first-year costs, but sampled PCa cases diag- ). These differences may be partly explained through variations in patterns of care between study periods. Penberthy et al. demonstrated that surgery alone and surgery in combination with other nonsurgical treatment increased health-care costs relative to no treatment. Nonsurgical treatment also increased costs, but to a lesser degree. In our study, approximately 19% of patients received either surgery alone, or in combination with other medical care vs the 11% observed in study by Penberthy et al. Similar proportions of patients in both studies received no treatment as initial therapy. A study conducted by Litwin et al. 17 found that the rate of prostatectomies in the United States began to First-year costs of prostate cancer CG Roehrborn et al increase during the late 1980s and continued to climb until peaking in 1992. This may partly explain the higher rates of surgery observed in the current study vs Penberthy et al. This study is subject to several limitations. The Medicare claims are primarily used for administrative purposes in obtaining reimbursement for services provided to Medicare-eligible patients. Research is not the intended purpose of these data. 18 The population observed during this study was limited to Medicare patients aged 65 years or older. Because older men are more likely to receive expectant management as initial therapy, the cost estimates presented here are probably lower compared to a cohort of younger men. In addition, the selection of initial treatment for equal stages might differ depending on patients' age at presentation, thus influencing both initial treatment choices and total cost if a younger population would be considered. Also, during the observation period, the choice of radiation treatment shifted from 3D conformal to intensity-modulated radiation therapy (IMRT) with associated higher cost. A study conducted by Brandeis et al. 12 found that initial PCa therapy costs varied from $15 301 to 31 329, depending on the treatment modality received. The use of the Medicare claims to estimate medical costs is also limited to what Medicare covers for the services utilized by patients. During the study period available, Medicare did not cover oral hormone therapy or other prescription drugs commonly used to treat pain or infection. We have defined PCa-related costs as the incremental difference between monthly costs among PCa patients and a cohort of patients without cancer. This is an indirect method of estimating costs related to the treatment of a disease. However, in an administrative database it is difficult to identify all costs directly related to the treatment of a specific condition using procedure and diagnostic codes. This is especially true if patients with PCa are utilizing general, non-PCa-specific medical care to a greater degree compared with non-cancer patients, as this type of care cannot be identified using administrative codes.
A small percentage of PCa cases (2.6%) selected for study inclusion developed primary cancers other than PCa during the first year of follow-up. In a sensitivity analysis excluding patients with PCa and other primary cancers, we were able to determine their effect on study results. Overall, first-year PCa-related costs excluding patients with PCa and other primary cancers were $512 lower compared to the analysis including these patients ($12 579 vs 13 091). First-year PCa costs, by initial stage (stage I: $11 068, stage II: $11 687, stage III: $13 499, stage IV: $17 820) were also lower. However, as with our main results, costs increased relative to stage. Patients with other primary cancers in addition to PCa likely utilized more resources during the first treatment year, having the effect of driving costs higher. As overall costs were less than 5% higher with the inclusion of patients with other primary cancers, the study's conclusions do not change.
Initial cancer staging data are likely to be more accurate in patients undergoing prostatectomy compared to those receiving other PCa treatments such as radiotherapy. Owing to potential inaccuracies in staging of the non-prostatectomy treatments, there is the potential for confounding. Initial treatment costs are variable depending upon the primary therapy chosen, with nonsurgical treatments (that is, radiation) having lower costs compared to surgery. 12 In this study, stages I and II were more likely to receive radiotherapy as an initial therapy. If a greater proportion of these patients had stage misclassified vs higher PCa stages (due to the lower staging accuracy of radiotherapy), this could have introduced a downward bias to the stage I and II cost estimates and an upward bias to stages III and IV.
Conclusions
As screening modalities improve, patients are increasingly being diagnosed with PCa at younger ages and/or earlier stages. Physicians more and more often choose watchful waiting or active surveillance as treatment strategies in the elderly, whereas in the youngest men minimally invasive surgery is the treatment of choice and for middle-aged men treatment with either surgery or IMRT. The increasing popularity of minimally invasive surgeries, 19 the significantly increased cost of using IMRT vs 3D conformal radiation therapy and the albeit reluctant acceptance of active surveillance as a reasonable alternative are contributing to a rapid shift in the utilization of treatment interventions with significant implications regarding treatment costs. Interventions that prevent or delay the onset of PCa could become important strategies for containing costs. Our analyses shed light on the magnitude of first-year PCa-related costs and may be useful in estimating the potential economic benefits of prevention strategies.
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